Rule Out MI Panel

Please see report for interpretive data.
Interpretive data for Troponin T

Published clinical studies have shown elevations of cardiac troponin T in patients with myocardial injury as seen in stable or unstable angina, heart failure, myocarditis pulmonary embolism, pericarditis, arrhythmias, cardiac contusions, and cardiac transplants. Elevations are also notable in patients with rhabdomyolysis and polymyositis.

Troponins are released during the process of myocyte injury. While they are cardiac specific, they are not specific for MI and detectable levels may be seen in other disease states that involve the heart muscle (e.g. arrhythmia, acute aortic syndrome, acute heart failure, hypertensive crisis, myocarditis, pericarditis, pulmonary embolism and Takotsubo cardiomyopathy). In these disease states, serial sampling of troponin can help distinguish between acute and chronic myocyte necrosis. The ACC/ESC/AHA guidelines and the Universal Definition of MI recommend serial sampling with a rise or fall in troponin to distinguish between acute and chronic cTn elevations.

Results should be interpreted in conjunction with clinical presentation including medical history, signs and symptoms, ECG data and biomarker concentrations.

Biotin in specimens taken from patients on high-dose biotin therapy or supplements may intefere with at least one test in this panel and cause inaccurate test results. It is recommended that for patients receiving therapy with high biotin doses (> 5 mg/day), no laboratory test specimen should be collected until at least 8 hours after the last biotin administration.
Please Note: New Reference Range for CKMB and Troponin T effective 07/05/2022.